Palisade Bio, Inc. (PALI) vs Scribe Therapeutics Inc. (SCTX)

A side-by-side comparison of Palisade Bio, Inc. and Scribe Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

PALI

Palisade Bio, Inc.

$261M

$1.51HealthcareDelayed quote: Oct 6, 2026, 1:49 PM EDT

SCTX

Scribe Therapeutics Inc.

$267M

$16.50HealthcareDelayed quote: Oct 6, 2026, 1:49 PM EDT

Total return — PALI vs SCTX

growth of $100 · dividends reinvested · last 1y

PALI -27.9% (-27.9%/yr)SCTX +8.1% (+8.1%/yr)SCTX compounded faster over this window

PALI SCTX

Metrics side by side

Total return (annualized)

Metric	PALI	SCTX
Total return (1Y)	-8.78%	N/A
Total return CAGR (3Y)	-44.66%	N/A
Total return CAGR (5Y)	-76.02%	N/A
Total return CAGR (10Y)	-71.24%	N/A

SCTX is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full PALI analysis Full SCTX analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.